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1. Introduction
Lentiviral vectors (LV) are efficient vehicles for gene transfer in mammalian cells due to
their capacity to stably express a gene of interest in non-dividing and dividing cells. Their
use has exponentially grown in the last years both in research and in gene therapy protocols,
reaching 12% of the viral vector based clinical trials in 2011 [1]. This chapter reviews and
discusses the state of the art on the production of HIV-1- based lentiviral vectors.
1.1. Lentiviruses
Lentiviruses are human and animal pathogens that are known to have long incubation peri‐
ods and persistent infection. The time between the initial infection and the appearance of the
first symptoms can reach several months or years [2]. Nowadays lentiviruses are classified
as one of the seven genus of Retroviridae family. Lentivirus genus is composed by nine virus
species that include primate and non-primate retroviruses (Figure 1) [3].
All Retroviruses share similarities in structure, genomic organization and replicative proper‐
ties. Retroviruses are spherical viruses of around 80-120 nm in diameter [4] and are character‐
ized by a genome comprising two positive-sense single stranded RNA. Also, they have a
unique replicative strategy where the viral RNA is reverse transcribed into double stranded
DNA that is integrated in the cellular genome [5]. Together with the RNA strands, the enzymes
necessary for replication and the structural proteins form the nucleocapsid. The later is inside a
proteic capsid that is surrounded by a double lipidic membrane [6]. Connecting the lipidic
membrane and the capsid there are the matrix proteins. The lipidic membrane has its origin in
the host cells and presents at surface the envelope viral glycoproteins (Env) (Figure 2).
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Figure 1. Lentiviruses taxonomy by the International Committee on Taxonomy of Viruses (ICTV).
Within the Retroviridae family, retroviruses can be classified as simple or complex. The com‐
plex retroviruses include the lentiviruses and spumaviruses presenting a more complex ge‐
nome with additional regulation steps in their life cycle.
Figure 2. Schematic representation of a retrovirus particle. Abbreviations: NC – nucleopcapsid; MA – matrix; CA – cap‐
sid; SU – surface subunit of Env protein; TM – transmembrane subunit of Env protein; RT – reverse transcriptase; PR –
protease; IN – integrase.
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1.2. HIV-1 genome
HIV-1 genome has about 9-10 kb and is constituted by several non-coding sequences that
control gene expression and protein synthesis, and genes that code for regulatory and acces‐
sory proteins in addition to the structural and enzymatic genes gag, pol and env, common to
all retroviruses (Figure 3).
The gag gene codes for a polypeptide that is proteolytic cleaved by the viral protease (PR)
originating three main structural proteins: matrix (MA), capsid (CA) and nucelocapsid (NC).
The pro gene codes for a polypeptide that after cleavage by PR, during the virus maturation,
originates PR, reverse transcriptase (RT) and integrase (IN). These enzymes play critical
roles in the life cycle of retroviruses since their functions are the cleavage of viral polypepti‐
des (also involved in virus maturation), the reverse transcription of viral RNA to double-
stranded DNA (provirus) and the integration of the provirus into the cellular genome [7].
Finally the env gene encodes a polypeptide that is cleaved by cellular proteases in two pro‐
teins, the SU (surface) and TM (transmembrane) subunits. Together, these two proteins are
the structural units of the Env protein that will interact with cellular receptors of the host
cell allowing for virus entrance into the cell [10].
Flanking the retroviral provirus there are the 5’ and 3’ Long Terminal Repeats (LTRs) com‐
posed by the 3’ untranslated region (U3), repeat elements (R) and 5’ untranslated region
(U5). The LTRs contain the enhancer/promoter sequence that allows for gene expression, the
att repeats important for provirus integration and the polyadenylation signal (polyA).
The HIV-1 genome also has other six genes that code for two regulatory proteins (Tat and
Rev), and four accessory proteins: Vif, Nef, Vpr, and Vpu. Tat protein interacts with cellular
proteins and the mRNA TAR sequence acting by increasing the viral transcription hundreds
of times. Rev interacts with Rev Responsive Element (RRE), a cis-acting sequence located in
the middle of the env gene allowing the efficient nuclear export of unspliced or singly
spliced messenger RNA. The functions of accessory proteins are related with pathogenesis
of the virus and they are not crucial for the viral replication in-vitro.
The function of all HIV-1 proteins and their interactions with the host cells are not yet clear‐
ly understood but it is already reported that there are 2589 unique HIV-1–to–human protein
interactions that are formed by 1448 human proteins [8,9].
Additionally to the coding sequences, the lentivirus genome also has several non-coding cis-
acting sequences that play important roles in viral replication. The LTRs contains the Trans‐
activator Response element (TAR) for the interactions of the complex formed by the Tat
protein and transcriptional factors. After the 5’ LTR there are the primer binding site (PBS),
where the reverse transcription starts, and the packaging signal (Ψ). Within the pol sequence
there are also the central polypurine tract (cPPT) and the central termination sequence (CTS)
contributing both for the efficient reverse transcription. Further there are the RRE in the
middle of env gene and near the beginning of the 3´LTR the polypurine tract (PPT), a purine
rich region where the synthesis of the plus strand DNA during the reverse transcription
starts [10].
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Figure 3. Schematic representation of HIV-1 provirus genome. Abbreviations: LTR - long terminal repeat; attL and attR
- left and right attachment sites; U3 - 3’ untranslated region; R - repeat element; U5 - 5’ untranslated; TAR - transacti‐
vation response element; PBS - primer binding site; DIS - dimerization signal; SD - splice donor site; SA - splice acceptor
site; ψ - packaging signal; cPPT - central polypurine tract; CTS - central termination sequence; RRE - Rev response ele‐
ment; PPT - 3' polypurine tract; polyA - polyadenylation signal.
1.3. HIV-1 life cycle
The HIV-1 Life cycle starts when the Env glycoproteins GP120 located at surface of the viral
envelope bind the CD4 cellular receptor and co-receptor CCR5, CSCR4 or both. This binding
induces conformational changes of Env glycoproteins that allows for the fusion of the viral
envelope with the cell membrane and the consequent entry of the viral core into the cell.
Once inside the cell the capsid starts to disintegrate and the RT enzyme begins the reverse
transcription where a double-stranded proviral DNA is synthesized using one of the posi‐
tive single-strand viral RNA molecules as template. When reverse transcription is complet‐
ed the double-strand DNA now called provirus forms a complex with viral proteins (RT, IN,
NC, Vpr and MA) and cellular proteins termed pre-integration complex (PIC) that is import‐
ed to the cell nucleus by an ATP-dependent manner. It is this energy-dependent mechanism
that allows the transduction of non-dividing cells by lentiviruses, unlike γ-retrovirus.
In the nucleus the linear provirus is integrated into the cellular genome by the integrase.
Now all the requisites to produce new viruses are filled and the proviral DNA is transcribed
into mRNA by the cellular RNA polymerase II. Still inside the nucleus some transcripts suf‐
fer a splicing event. The mRNA transcripts are exported from the nucleus to cytoplasm to be
transcribed and to start to form the viral particles; two full-length RNA transcripts will be
packaged in the viral particles.
The assembly of the viral proteins and the viral RNA occurs near the cellular membrane, in
specific regions called lipid-rafts that are rich in cholesterol and sphingolipds. The immature
viral particles are released from cells by budding. After leaving the cells, the viral protease
cleaves the Gag and Pol proteins precursors to finally generate a mature infectious virion
(reviewed by [5,10]).
2. Lentiviral vector development
The development of lentiviral vectors (LVs) started in 1989 when an HIV-1 provirus with
achloramphenicol acetyltransferase (cat) reporter gene in place of the non-essential nef gene was
constructed. The transfection of Jurkat cells with this modified provirus plasmid produced in‐
fectious replicative competent viruses, very similar with wild-type HIV-1, that could be used
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as a tool for study HIV infection [11]. Few months after, the same group presented the first rep‐
lication-defective HIV-1 vector. In a trans-complementation assay for measuring the replica‐
tive potential of HIV-1 envelope glycoprotein mutants they used an identical HIV-1 provirus
construction but with a deletion in the env gene. The Env glycoproteins were supplied by an in‐
dependent expression plasmid. The co-transfection of these two plasmids allowed for the pro‐
duction of replication-defective viruses [12]. These vectors were structural identical to the
wild-type virus, but lacked in their genome the env gene. They could only perform a single cy‐
cle of replication because their host cells, after infection, did not have the env gene to produce
infectious virus. Although the principal aim of these studies was not the creation of viral vec‐
tors, they were the basis of lentiviral vector development, suggesting that lentiviruses could be
adapted as a tool for genetic material transfer and permanent modification of animal cells.
Other preliminary studies were being conducted and several important discoveries or inno‐
vations had also contributed for the development of LVs. The introduction of the resistance
marker gene hypoxanthine–guanine phosphoribosyl-transferase (gpt) under the expression con‐
trol of SV40 promoter in the place of env gene deletion allowed the first quantification of in‐
fectious LVs produced [13]. Like it had been observed for other γ-retroviral vectors (γ-RVs)
it was possible to produce infectious lentiviral particles with Env glycoproteins from other
viruses (pseudotyping); for example the Moloney Murine Leukemia Virus amphotrophic en‐
velope 4070A (A-MoMLV) [13], and Human T-cell Leukemia Virus Type I (HTLV-I) enve‐
lope [14] were successfully used suggesting that env gene was not necessary for virion
particle formation. The localization and sequence of packaging signal was identified as the
main responsible for the packaging of viral RNA [15] suggesting that modified RNAs with
Ψ could also be packaged into virions. The discovery of the great stability conferred to LV
pseudotyped with Vesicular Stomatitis Virus-G protein protein (VSV-G) allowed to concen‐
trate the LV up to 109 by ultracentrifugation or ultrafiltration without significant loss of in‐
fectivity [16,17]. It was shown that LVs can transduce efficiently non-dividing cells, their
principal advantage over the oncoretroviral vectors [16,18,19].
All these steps showed the potential of using modified lentiviruses as vectors, stimulating
the iterative studies and the evolution of LVs in the next years. Their further development
was based in safety principles (most of them already used in the development of oncoretro‐
viral vectors) such as the splitting of the genome into several independent expression cas‐
settes: the packaging cassette with the structural and enzymatic elements, the transfer
cassettes with the gene of interest and the envelope expression cassette. In addition, the
elimination of non-essential viral elements and the homology reduction among the expres‐
sion cassettes also contributed to avoid the possibility of recombination, vector mobilization
and the generation of replicative competent lentiviral vectors (RCLVs).
2.1. Four generations of packaging constructs
Four generations of LVs are currently considered; these differ from each other in terms of
the number of genetic constructs used to drive the expression of the viral components, the
number of wild-type genes retained as well as the number and type of heterologous cis-ele‐
ments used to increase vector titers and promote vector safety.
Lentiviral Gene Therapy Vectors: Challenges and Future Directions
http://dx.doi.org/10.5772/52534
291
The system of three expression cassettes developed in 1996 by Naldini et al. [16] is consid‐
ered the first generation of LVs. In this system the packaging cassette has all structural pro‐
teins, with exception of Env glycoproteins, and all accessory and regulatory proteins. Later
the 5’ LTR was substituted by a strong promoter (CMV or RSV) and the 3’ LTR by an SV40
or insulin poly(A) site to reduce the homology between the cassettes. To prevent the packag‐
ing of viral elements the Ψ and PBS were deleted. In the env expression cassette the gp120
from HIV-1 was replaced by other env genes as VSV-G or amphotrophic MLV envelope
(Figure 4). Finally the transgene cassette was composed by the 5’ LTR, the ψ with a truncat‐
ed gag gene, the RRE cis-acting region and the gene of interest under the control of a heterol‐
ogous promoter (usually CMV) and the 3’LTR [16,20].This system allowed in an easy way to
achieve good titers but its level of safety was not very high. RCL could be generated just
with three recombination events by homologous recombination between the viral sequences
in all cassettes or endogenous retroviral sequences in cells. In order to improve the safety
and decrease the cytotoxicity of LVs, the three plasmid system was maintained, but all ac‐
cessory genes not required for viral replication in vitro (vif, vpr, vpu, and nef) [21] were re‐
moved without negative effects on vector yield or infectivity. And in this way the second
generation of LVs was developed (Figure 4) [22–25]. In the second generation, if by chance
some RCL was generated, it would be unlikely to be pathogenic [26]. However the number
of homologous events to generate RCL was the same as in the previous generation.
Reducing the lentiviral sequences by eliminating the tat and place the rev in an independent
plasmid was the further step that originated the third generation of LV [27]. The tar sequence
was replaced by a strong heterologous promoter. Therefore Tat protein was no longer neces‐
sary to increase the transgene transcription and tat gene was eliminated. This contributed for
the reduction of lentiviral elements in the constructs. Rev was placed in an independent non-
overlapping plasmid increasing the safety since now four events of homologous recombina‐
tion were required for RCL formation [27]. With these new features, the vectors of third
generation (Figure 4) presented a higher level of biosafety and, as the titers did not decreased,
their use was widespread. Today they are the most commonly used LVs.
Although the formation of RCL was improbable, homologous recombination between the
constructs was still possible since RRE sequence and part of packaging sequence in gag gene
was in both transfer and structural packaging constructs. To solve these problems other sol‐
utions were developed originating the fourth generation of LV. The first approach used con‐
sisted in the replacement of the RRE sequences by heterologous sequences with similar
functions that do not need the Rev protein. Some of these sequences were the Mason-Pfizer
monkey virus constitutive transport element (CTE), the posttranscriptional control element
(PCE) of the spleen necrosis virus and the human nuclear protein Sam68 [28–31]. The heter‐
ologous sequences increased the stability of the transcripts allowing their nuclear export.
However the titers have decreased.
In 2000 a different approach based on codon optimization was implemented in lentiviral
vector design [33]. This approach consists in perform silent mutations, changing the codon
that codes for a certain aminoacid for other that codes for the same aminoacid, in principle,
with a higher intracellular availability [32]. Applying this to the packaging and transfer con‐
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structs the homology between them was eliminated. These changes also allowed an inde‐
pendent expression of Rev since the sequences with suboptimal codon usage in HIV-1
genome, that conferred RNA instability and consequently lower expression, disappeared
[32]. In the fourth generation (Figure 4) the homology between constructs were severely re‐
duced but the titers had also been affected comparing with systems with the Rev/RRE [32].
Also, with the independence of Rev/RRE system, the level of biosafety decreased since the
number of homologous recombination events for RCL formation was again three. Maybe
due to these drawbacks the fourth generation has not been extensively used. However the
codon optimization technology had been used to decrease the homology between sequen‐
ces, improve the expression of viral components and viral titers [33].
Regarding the biosafety concerns about RNA mobilization and the possibility of generating
RCLs, other improvements in packaging constructs were used and tested in transient LVs
productions. These improvements relied on the concept of split-genome used for retroviral
and lentiviral vector development but this time applied to the packaging construct. The gag-
pol sequences were divided by two or three independent expression cassettes, disarming the
functional gag-pol structure that is essential for vector mobilization [34]. In these systems ad‐
ditional recombination events between the several expression cassettes are necessary to gen‐
erate RCLs which seems to contribute to a significant decrease of recombinant vectors
formation with a functional gag-pol structure [35,36]. Although this increased LV safety the
transduction efficiency and the LV production are challenged by the higher number of plas‐
mids required [37].
Figure 4. Schematic representation of the four generations of lentiviral packaging constructs: A) First generation
packaging vector. B) Second generation packaging vector. C) Third generation packaging vector. D) Fourth generation
packaging vector.
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2.2. Transfer vector
The transfer vector is the expression cassette of the transgene that will be packaged into the
viral vector and integrated in the cellular genome of the target cells. Besides the gene of in‐
terest and the commonly heterologous promoter for transgene expression, the transfer ex‐
pression cassette must have: the sequences responsible for the expression of the full-length
transcript and its packaging into the newly formed virions in the producer cells; the sequen‐
ces that will interact with viral and cellular proteins to allow an efficient reverse transcrip‐
tion, transport into the cellular nucleus and proviral integration into target cells genome.
Despite the simple design and the lack of sequences that code for viral proteins, the transfer
vector also evolved over the time. This evolution was primarily focused on safety by reduc‐
ing and replacing the viral sequences by heterologous elements and in optimizing both safe‐
ty and efficiency by the addition of several cis-acting elements to the transfer cassette [10].
The transfer vectors usually used in the first and second generation of packaging constructs
LVs were composed by the 5’ LTR which include the TAR sequence, the PBS, the SD, the Ψ,
the 5’ part of gag gene, the RRE sequence, the SA, an heterologous promoter followed by the
gene of interest, the PPT and polyA within the 3’ LTR. The first hundreds of base pairs of
gag are included after the packaging signal to increase the packaging efficiency (Figure 5).
To avoid gag translation the initiation codon is usually mutated or cloned out of frame
[16,20]. However, like it was previously found for γ-RVs, this transfer vector design with
both wild-type LTRs can lead to integration genotoxicity and facilitates the mobilization of
the transgene in the case of posterior infection of transduced cells [38]. To overcome these
biosafety problems the LTRs of the transfer vector suffered additional changes. One of the
first modifications was the replacement of the enhancer/promoter and Tar sequence of the 5’
LTR by a strong heterologous promoter allowing the transcription of the full-length viral
RNA in a Tat-independent manner [25]. In addition the wild-type enhancer/promoter se‐
quences in the U3 region of the 3´LTR were deleted originating the self-inactivating (SIN)
LVs [27,39,40], as it had already been done for γ-RVs [41].
The SIN design (Figure 5) generates in the target cells a proviral vector without enhancer/
promoter sequences in both LTRs. In producer cells the packaged RNA transcript does have
the heterologous promoter in the 5’ end. Afterwards, in the target cells, during the reverse
transcription, the U3 region of 3’ LTR is copied and transferred to the 5’LTR. This transcrip‐
tional inactivation offered by the SIN design presents several safety advantages: prevents
the formation of potentially packageable viral transcripts from the 5´LTR and consequently
prevents vector mobilization by prior infection with a replicative retrovirus [39,42]; reduces
the risk of insertional mutagenesis induced by the transcriptional interference of the LTRs in
the neighboring sequences that can lead to the activation or up-regulation of oncogenes [43];
and lowers the risk of RCL formation by the reduction of the sequences with homology with
wild-type virus.
The adoption of SIN design did not affected LV production as it happened with γ-RVs
[27,39,40,44]. However both LVs and γ-RVs displayed high frequencies of read-through of
the 3' polyadenylation signal which can lead to the transcription of cellular sequences as on‐
cogenes. This inefficient termination of transcription could suggest that some of the enhanc‐
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er/promoter sequences deleted can have a role in an efficient transcription termination [45].
In this context several improvements were done by the addition of heterologous elements to
increase safety, expression and efficacy of LVs: heterologous polyadenylation signals in the
3´LTR could increase the efficiency of LVs and are particularly beneficial in the case of SIN
LVs avoiding the read-through of cellular genes [40,46]; the chromatin insulators as the
chicken hypersensitive site 4 (cHS4) sequence core from the β-globin locus control region
(LCR) can reduce the interference from the neighboring regions in the vector and transgene
expression [48]. Also these can improve the LV safety avoiding the full-length vector tran‐
scription or reducing long-distance effects of the integrated transgene promoter on neigh‐
boring cellular genes in the target cells. Additionally to the increased safety, insulators can
help to maintain the gene expression over time preventing transcriptional silencing events
in both producer and target cells [47–49]; incorporation of certain post-transcriptional regu‐
latory elements (PRE) like the woodchuck hepatitis virus posttranscriptional regulatory ele‐
ment (WPRE) near the 3’ untranslated region can also decrease the read-through in SIN
vectors increasing the transgene expression and viral titers, [50–53]. The firsts WPRE se‐
quences used contained part of a sequence that codes for a protein (WHV X) that has been
reported a few times as related with carcinoma formation, posing safety concerns. However
a further improved WPRE was created without this potential harmful sequence [54]; The
cPPT sequence contributes for efficient reverse transcription and the proviral nuclear import
processes. Although this non-essential sequence was not used in the firsts transfer vectors,
its re-insertion increased the gene transfer efficiency [55–57].
Figure 5. Schematic representation of a non-SIN transfer vector (A) and a SIN transfer vector (B).
3. Pseudotyping
LVs, as other retroviral vectors, can incorporate in their viral particles Env glycoproteins
from other enveloped viruses, a feature denominated pseudotyping. This was firstly demon‐
strated for the HIV-1-based lentiviral vector using a Moloney Murine Leukemia Virus am‐
photropic envelope 4070A (A-MoMLV) [13] and an Human T-cell Leukemia Virus Type I
(HTLV-I) envelope [14].
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In general the pseudotyped LVs have the tropism of the virus where glycoproteins are de‐
rived from, but there are some exceptions such as the glycoprotein of the Mokola virus,
where the pseudotyped vectors did not presented the specific neurotropism of the paren‐
tal virus [58]. This ability of LVs to be pseudotyped showed to be advantageous since sev‐
eral  glycoproteins  could  be  tested  to  improve  the  transduction  of  cells  with  different
receptors.  As  an example,  HIV-based LVs pseudotyped with glycoprotein  derived from
the Rabies virus PV strain exhibited a great  efficiency and neuronal  tropism among the
tested envelopes [59].
In addition to the tropism of LVs, the Env glycoproteins also affect vector structure and sta‐
bility, the interactions with the target cells and the LV behavior during the infection. One
example is LVs pseudotyped with rabies virus glycoprotein which allow for the retrograde
axonal transport and access to the nervous system after peripheral infection [60]. Another
example is the stability conferred to LVs by the VSV-G glycoproteins. The VSV-G glycopro‐
teins are one of the most used Env proteins due to their wide tropism, with high titers ach‐
ieved, great stability and resistance conferred to the LVs that allows for their concentration
by ultracentrifugation. In addition they resist to freeze-thaw cycles, an important factor for
storage of the vectors [16,18,19,61]. Despite these positive characteristics, the VSV-G protein
is toxic for producer cells if expressed constitutively [17] and is inactivated by human serum
complement [62], although this inactivation can be minimized using VSV-G conjugated with
poly(ethylene glycol) [63].
Up to the present, several glycoproteins were used to pseudotype LVs (Table 1) each one
presenting specific advantages and disadvantages that also depend on the LV application.
Although LVs pseudotyped with different Env glycoproteins present different tropisms, be‐
ing some tropisms more selective than others, in general these are not specific for a particu‐
lar cell type as happens with HIV-1 glycoproteins [80,81]. For instance, the Ebola Zaire
(EboZ) glycoprotein seems to be superior to other glycoproteins in the transduction of apical
airway epithelia [72]. However also has been shown to transduce liver, heart, and muscle
tissues [82].
This lack of specificity is not ideal from a clinical point of view, especially for in vivo gene
therapy applications since it can lead to the infection of cells that do not need to be trans‐
duced [83].
Several strategies have been used to increase the specificity of infection in order to retarget
the LVs to a cell of interest. These strategies consisted in genetic engineering of virus envel‐
ops by deletion of some domains or fusing molecule-ligands (growth factors, hormones,
peptides or single-chain antibodies) in several locations of the viral glycoproteins. The pur‐
pose is to choose cellular receptors specifically expressed on the target cells that will interact
with the chimeric glycoproteins, restricting this way the vector tropism. A successful exam‐
ple was the removal of the heparan sulfate binding domain from the Sindbis virus envelope
protein which effectively restricted the tropism of pseudotyped LVs to dendritic cells. This
genetic modified Env protein interacts solely with the C-type lectin-like receptor almost ex‐
clusively on primary dendritic cells unlike its natural counterpart [84].
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Species/Envelope Vectors Comments References
Vesicular stomatitis virus (VSV-G)
HIV-1
HIV-2
FIV
EIAV
SIV
BIV
JDV
CAEV
Very wide tropism. Presents resistance to
high-speed centrifugation.
Cytotoxic for producer cells if expressed
constitutively.
Susceptible to complement-mediated
degradation which can be minimized by
PEGylation
[16][64][65][66][66][66][67 -
67][67 – 69]
Feline endogenous
retrovirus (RD114)
HIV-1
SIV
More efficient and less toxic than VSV-G in
cells of the hematopoietic system [70][71]
Ebola HIV-1 Efficiently transduces airway epithelium [72]
Lymphocytic choriomeningitis
virus (LCMV)
SIV
HIV-1
FIV
Low toxicity [73]
Rabies HIV-1 Rabies confers retrograde transport inneuronal axons [24]
Mokola EIAV Mokola selectively transduces RPE uponsubretinal injection [24][74]
Ross River virus HIV-1FIV
Transduces hepatocytes, glia cells and
neurons [75][76]
Sindbis virus HIV-1 pH-dependentendosomal entry. Useful forvector targeting [77]
Influenza virus hemagglutinin HIV-1 Transduces airway epithelium [72]
Moloney murine leukemia virus
4070 envelope
HIV-1
SIV Able to transduce most cells [18][16]
Table 1. Lentiviral Vectors pseudotyped with various heterologous viral glycoproteins. Adapted from [78,79].
The envelope proteins engineered by fusion of natural ligands were in general able to bind
to target cells. However the fusion domain of Env resulted generally in low vector titers
since the ligand inhibits the fusogenic properties of the Env protein that allows for viral en‐
try [85]. This approach seems to be more challenging but there are already improvements.
One example is the LV pseudotyped with a chimeric glycoprotein of Sindbis virus covalent‐
ly linked with mouse/human chimerical CD20-specific antibody which resulted in specific
and stable transduction of CD20+ human lymphoid B cells. In this case the membrane fusion
is triggered by the glycoprotein, in a pH-dependent manner, and it happens inside endocyt‐
ic vesicles formed after antibody binding [86].
Other glycoproteins and ligands are being tested and used as well as alternative strategies to
improve infection specificity of LVs [87–91].
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4. Lentiviral vector production
The continuous research in LV development in the last twenty years and the acquired
knowledge from the previous development of γ-RVs allowed the production of LVs with a
significant biosafety level. However to apply LVs to clinical use they need to be easily and
inexpensively produced and purified at a large-scale since, high concentrations of lentiviral
particles are usually needed for efficient gene transfer in primary cells and the treatment of a
single patient may require several liters of viral supernatant [92,93]
For large-scale and clinical-grade LV productions, a stable LV producer cell line seems to be
the best approach for increased safety and well characterized production process. However,
unlike γ-RVs, the development of LV packaging cell lines has been more challenging be‐
cause of the cytotoxicity of some viral proteins like Tat, Nef, Vpr, Rev and PR [94]. Also
VSV-G envelope, the typically envelope of choice for LV production because of its wide
tropism and stability conferred to viral particles, is toxic for the producer cells. The VSV-G
envelope can however be replaced by other non-toxic envelopes as the feline endogenous
virus RD114 or the amphotropic MLV 4070A Env glycoproteins [33,95] and thus among the
cytotoxic lentiviral proteins just the protease is still necessary for lentiviral vector produc‐
tion with the current packaging systems [93].
HIV protease mediates its toxicity in vitro and in vivo by cleaving procaspase 8, originating
the casp8p41 fragment. This fragment induces mitochondrial depolarization leading to mi‐
tochondrial release of cytochrome C, activation of the downstream caspases 9 and 3 and nu‐
clear fragmentation [96–98]. This cytotoxicity has hampered the development of stable cell
lines.
The most used cells for LV production are the human embryonic kidney HEK-293 cell line
and its genetic derivates the 293T (expressing the SV40 large-T antigen) and 293E (express‐
ing the Epstein-Barr virus nuclear antigen-1, EBNA-1) cell lines. For clinical application hu‐
man 293 and 293T cells have been the exclusive cell substrates [93]. Both cell lines can be
used to produce LV in adherent systems and both can be easily adapted to serum-free sus‐
pension cultures. The 293T cells are most widely used because presents superior LV pro‐
ductivities  compared with  HEK-293  cells.  However  the  HEK-293  cell  line  may have  an
advantage in terms of safety as it lacks the SV40 large T antigen encoding gene (expressed
in 293T cells) which is oncogenic [93,99,100]. In some research works other human or mon‐
key derived cells have been used (other 293 derived clones, HeLa, HT1080, TE671, COS-1,
COS-7, CV-1), although most of them showed lower LV titers [101]. However, COS-1 cells
have shown to be capable of producing 3-4 times improved vector quality (expressed in in‐
fectious vector titer per ng of CA protein, p24), comparing with 293T cells, under serum-
containing conditions [102].
4.1. Transient lentiviral vector production
Commonly LVs are produced by co-transfecting cells with the several expression cassettes
harboring the transgene and the viral elements using chemical agents (e.g. calcium phos‐
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phate or polyethylenimine) and after 24 to 72 hours the LV are harvested [93]. This produc‐
tion system is fast and can be easily adapted to produce LVs with new genes of interest or
with other Env glycoproteins. It is a simple process to apply at small scales commonly used
in research, unlike the laborious development of a packaging cell line. However transient
production is not the ideal choice for large and clinical LV productions since it is difficult to
scale-up and requires large amounts of Good Manufacturing Practices (GMP) grade plasmid
expressions cassettes turning the production more expensive [93,103]. In addition, transient
LV production brings some biosafety problems like recombination between expression cas‐
settes that could originate or facilitate the RCL formation. The recombination can occur in
the mixture of transfection, inside the producer cells or during reverse transcription in the
target cells since, generally after transfection cells have several copies of the plasmids which
can contribute for the co-packaging of RNA transcripts [33,104]. Also batch to batch variabil‐
ity is common in transient productions since a population of transfected cells that expresses
viral elements from episomal cassettes is generated. This can further complicate biosafety
validation steps.
Nevertheless transient LV production is commonly used and recently it was shown that
high titers of HIV-based LVs for clinical applications can be obtained by transient calcium
phosphate transfection at large-scale under GMP conditions (Table 2) [99].
Cell origin Vector Packaginggeneration Envelope
Maximal titers
(I.P./ml) Observations Reference
293 E SIN HIV-1based 3
rd VSV-G 1x106 PEI-mediatedtransfection [107]
HEK293 HIV-1based 3
rd VSV-G 1x108 PEI-mediatedtransfection [101]
293T HIV-1based 3
rd VSV-G 2x109 Transfection withcalcium phosphate [99]
293T HIV-1based 3
rd VSV-G 1x108 Transfection by FlowElectroporation [105]
Table 2. Transient LV productions. In this table they are presented several features of recent lentiviral productions in a
transient manner.
There are several transfection agents that can be used to transfect mammalian cells as cal‐
cium phosphate, polyethylenimine (PEI) and cationic molecules (such as LipofectAMINE®
and FuGENE®). For large scale only Ca-phosphate and PEI are used since the others are
much more expensive.  Both reagents are efficient but PEI is  usually preferred since Ca-
phosphate efficiency is highly sensitive to pH variations and can require serum or albu‐
min  to  reduce  Ca-phosphate  cytotoxicity,  unlike  PEI  [93].  However  their  use  can  raise
some purity  problems and can be cost-ineffective.  Recently a  method that  does not  use
chemicals for transfection, flow electroporation, was used for transiently LV production at
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large-scale  [105].  The  electroporation  systems  are  normally  used  to  transfect  small  vol‐
umes but flow electroporation addresses this  limitation by continuously passing the de‐
sired volume of a cell and DNA suspension between two electrodes [106]. The procedure
can be effectively scaled up for large bioprocessing avoiding additional costs and purifica‐
tion problems (Table 2) [105].
4.2. Stable lentiviral vector production
To overcome the biosafey problems in LV transient productions, inducible packaging cells
lines have been developed (Table 3). The development of these systems is more time-con‐
suming since after insertion of each expression cassette the population of stably transfected
cells is usually screened for the best producer clone, like for γ-RVs, to maximize the LV pro‐
duction. However, these packaging cell lines are derived from one clone, therefore all the
cells have the same growth and LV production behavior being the LV productions reprodu‐
cible. This allows the generation of GMP cell banks, increasing safety conditions.
Cell origin Vector Packaginggeneration Envelope
Maximal titers
(I.P./ml) Observations Reference
293T HIV-1based 2
nd VSV-G 1x107 Tet-off [108]
293T HIV-1based 3
rd VSV-G 1.8x105
Ecdysone inducible
system. Codon-
optimized gag-pol
[109]
293T SIV-based 3
rd VSV-G 1x105
Ponasterone inducible
system. Codon-
optimized gag-pol
[110]
293T HIV-1based 2
nd VSV-G 3x105
Tet-off.
Codon-
optimized gag-pol
[103]
293T HIV-1based 3
rd VSV-G 3.4x107 Tet-on [111]
293T EIAVbased 3
rd VSV-G 7.4x105 Tet-on [112]
293T SIV-based 3
rd VSV-G 5x107
Introduction of vector
by concatemeric array
transfection.
Tet-off
[113]
293T HIV-1based 2
nd
Ampho
GaLV
RDpro
1.2x107
1.6x106
8.5x106
Continuous system.
Codon-optimized gag-pol [33]
Table 3. Lentiviral vector packaging cell lines. In this table they are presented several features of available packaging
cell lines for LV production.
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In conditional packaging cell lines the expression of cytotoxic proteins is under control of
inducible promoters and the number ofcells and growth conditions can be controlled, start‐
ing the LV production at a defined moment by adding an inductor or removing the suppres‐
sor from the culture medium. Originally the titers were low but further improvements in the
expression cassettes design and optimization of the induction parameters led to similar lev‐
els of transient productions. However, such systems can only produce LV for a few days be‐
cause of the activity of the cytotoxic viral proteins. In addition these packaging cells have
often shown to be instable due to leaky expression of the cytotoxic viral elements that are
under control of the inducible promoters and the need to add an inductor to the medium in
some systems can add further difficulties to the purification process [93].
In 2003 Ikeda and co-workers have reported the development of a non-inducible packaging
cell line that continuously produces LV for three months in culture (Table 3). However, sig‐
nificant titers could only be obtained after MLV-based vector transduction. This procedure
raises serious problems from the biosafety point of view, since it increases the chances of
RCL by homologous recombination, posing further concerns of co-packaging [37]. Never‐
theless it was shown that it is possible to establish a cell line that can continuously produce
LV although, until now no additional reports for this system appeared.
5. Lentiviral vector applications
Lentiviral vectors have emerged as powerful and versatile vectors for ex vivo and in vivo
gene transfer into dividing and non-dividing cells. The particular characteristics of LVs al‐
lied to their marked development during the last years have triggered the attention of differ‐
ent fields, consequently a vast range of applications for these vectors, from fundamental
biological research to human gene therapy have appeared. One of the applications of LVs is
in genome-wide functional studies. The combination of synthetic siRNAs (small interfering
RNA) or shRNAs (short hairpin RNAs) that can suppress the expression of genes of interest
in mammalian cells [114], with engineered LVs allowed the formation of libraries like the
Netherlands Cancer Institute (NKI) libraries, the RNAi consortium (TRC) libraries, the Han‐
non–Elledge libraries, and the System Biosciences (SystemBio) libraries for high-throughput
loss-of-function screens in a wide range of mammalian cells [115]. For example, the TRC
shRNA library has nearly 300,000 shRNAs targeting for 60,000 human and mouse genes
[116]. The ability of LVs to achieve stable high-efficiency gene silencing in a wide variety of
cells including primary cells, that are difficult to transduce, or non-dividing cells such as
neurons thus greatly expanded the possibility of the RNAi screens [117].
Other application for LVs is in animal transgenesis. Genetic-modified animals can be created
by infection of fertilized or unfertilized oocytes, single-cell embryos, early blastocysts, em‐
bryonic stem cells or by transduction of cells that are used as donors of nucleus for somatic
cell nuclear transfer (SCNT) [10]. These animals (transgenic mices, rats, pigs, cows, chicken,
monkeys) are used to understand gene function or biological processes, for validation of
drug targets, for production of human therapeutic proteins and as preclinical models for hu‐
man diseases [118].
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Lentiviral vectors are being increasingly used for the cell genetic modification leading to
cell-engineering applications. Stable gene transduction can be used for in vivo imaging of
vector infected cells. In vivo imaging studies of cells, including stem cells, have become in‐
creasingly  important  to  understand cell  distribution,  differentiation,  migration,  function,
and transgene expression in animal models. As an example, LVs expressing the firefly luci‐
ferase  gene  were  used to  monitor  human embryonic  stem cell  (hESC)  engraftment  and
proliferation in live mice after transplantation [119].  LVs can also be used to cellular re‐
programming of somatic cells. More specifically, the promising induced pluripotent stem
cells (iPS) can be generated from a somatic cell by transduction of four key transcription
factors,  Oct4,  Sox2,  Klf4,  and c-Myc,  using LVs[120,121].  iPS can be used to study stem
cell  biology,  as  a  cellular  platform  for  pharmacological  and  toxicological  [122]  and  are
considered a  possible  source  of  autologous  stem cells  for  use  in  regenerative  medicine.
LVs also have been used in biotechnology to engineer cell lines for the production of pro‐
teins of interest [123].
The main goal of LV technology is their use in clinical gene therapy applications. Within
this  purpose  considerable  efforts  have been made to  increase  the  safety  and efficacy of
LVs. Proof-of-concept has been established in preclinical animal models since several re‐
search groups have reported that LVs could treat or cure a disease including β-thalassae‐
mia[124],  sickle  cell  anemia  [125],  hemophilia  B  [126]  and  ζ-chain-associated  protein
kinase of 70 kDa immunodeficiency [127]. Moreover, improvements in other genetic disor‐
ders like Parkinson’s disease [128], cystic fibrosis [129] and spinal muscular atrophy [130]
have been reported.
LVs have more recently moved beyond the preclinical stage into the clinical arena. The first
human clinical trial using LVs was initiated in 2003. In this, a VSV-G-pseudotyped HIV-
based vector was engineered to conditionally express an antisense RNA against envelope
glycoprotein in the presence of regulatory proteins provided by wild-type virus. Five sub‐
jects with chronic HIV infection received a single dose of gene-modified autologous CD4+ T
cells which resulted in an increase of CD4+ T cells (in four out of the five subjects) and de‐
crease in the viral load (in all five participants) after 1 year. Further studies over 2 years have
not detected any adverse clinical events [131].
Since this first gene therapy clinical trial until June 2012, about 54 gene therapy clinical tri‐
al using LVs are ongoing or have been approved. Among them there are 12 trials for the
treatment of HIV infection, 22 for the treatment of monogenic diseases (X linked cerebral
adrenoleukodystrophy,  Sickle  cell  anemia,  Wiskott-Aldrich  Syndrome,  Metachromatic
Leukodystrophy, X-Linked Chronic Granulomatous Disease, Inherited Skin Disease Neth‐
erton Syndrome, mucopolysaccharidosis type VII, β-thalassemia, Fanconi Anemia Comple‐
mentation  Group  A,  X-Linked  Severe  Combined  Deficiency,  Adenosine  Deaminase
Deficient Severe Combined Immunodeficiency, Hemophilia A), 15 against various cancers,
2 for Parkinson’s disease, 3 for ocular diseases and 1 for patients with Stargardt Macular
Degeneration [1].
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6. Conclusions and outlook
The major concerns associated with the use of all retroviral vectors are the formation of rep‐
lication competent retroviral vectors (RCR), the mutational integration of the provirus into
the host cellular genome and mobilization of structural viral genes to target cells. In addi‐
tion, the majority of developed LVs are HIV-derived raising further safety concerns since
this is a well known human pathogen. Significant efforts have been made to develop LVs
with improved biosafety and increased transduction efficiency. Some of those biosafety fea‐
tures include the splitting of viral elements by several expression cassettes, the use of self-
inactivating vectors (SIN), decreasing to a minimum the number of viral elements and
reducing homology between them.
Lentiviral vectors have already won its place as valuable and flexible tool for gene delivery,
being used in several applications but further research is still ongoing towards the develop‐
ment of a lentiviral vector providing higher titers, higher robustness, lower toxicity and
higher biosafety.
Lentiviral vector gene therapy is becoming a real alternative vector for therapy with dozens
of clinical trials either been already performed or ongoing. These, together with the future
incoming clinical trials, will enable to assess overall the pros and cons of the newcomer len‐
tiviral vectors and will provide insights to further vector innovations that will be important
to increase their productivity, quality and safety.
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